COMPARATIVE IN VITRO ACTIVITIES OF PEFLOXACIN, OFLOXACIN, ENOXACIN AND CIPROFLOXACIN AGAINST 256 CLINICAL ISOLATES
- 1 September 1987
- journal article
- research article
- Published by Wiley in Acta Pathologica Microbiologica Scandinavica Series B: Microbiology
- Vol. 95B (1-6) , 141-146
- https://doi.org/10.1111/j.1699-0463.1987.tb03102.x
Abstract
The antibacterial activity of four new fluoroquinolone carboxylic acids, pefloxacin, ofloxacin, enoxacin and ciprofloxacin, against 256 clinical isolates was investigated by means of an agar dilution method. Generally, all quinolones tested had a high activity against Gram-negative bacteria. More than 90% of Enterobacteriaceae strains were inhibited by a quinolone concentration of 0.4 .mu.g/ml. Also strains usually resistant to conventional .beta.-lactam antibiotics, and sometimes to third-generation cephalosporins, like Enterobacter spp., Serratia spp. and Yersinia spp. were susceptible to the tested quinolones. Ciprofloxacin was 5 to 25-fold more potent on a weight basis against Enterobacteriaceae than the other quinolones. Neisseria meningitidis, Neisseria gonorrhoeae, and Haemophilus influenzae were extremely susceptible to the new quinolones. Ciprofloxacin was about 10 times more potent against Pseudomonas aeruginosa than the other quinolones, and was the only quinolone that was sufficiently active against all tested P. aeruginosa strains (MIC .ltoreq. 0.4 .mu.g/ml). The activity against Gram-positive bacteria was considerably lower. All the quinolones investigated had an acceptable activity against many of the methicillin-sensitive and methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci. The majority of the Streptococcus ssp. tested was quinolone-resistant, as was Listeria monocytogenes. Generally, it was evident that ciprofloxacin was more potent on a weight basis than the other quinolones, but this difference was counterbalanced by a higher achievable serum concentration for oxfloxacin. Some of the investigated fluoroquinolones might constitute valid therapeutical alternatives to .beta.-lactam antibodies and aminoglycosides in the treatment of serious bacterial infections.Keywords
This publication has 30 references indexed in Scilit:
- In vitro activity of Ro 23-6240, a new fluorinated 4-quinoloneAntimicrobial Agents and Chemotherapy, 1986
- In-vitro activity of newer quinolones against aerobic bacteriaJournal of Antimicrobial Chemotherapy, 1986
- Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acidAntimicrobial Agents and Chemotherapy, 1984
- In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivativesAntimicrobial Agents and Chemotherapy, 1984
- Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteriaAntimicrobial Agents and Chemotherapy, 1984
- Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological studyJournal of Antimicrobial Chemotherapy, 1984
- Investigations into the mechanism of action of the antibacterial agent norfloxacinJournal of Antimicrobial Chemotherapy, 1984
- In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprimAntimicrobial Agents and Chemotherapy, 1983
- In vitro activity of ciprofloxacin (Bay o 9867)Antimicrobial Agents and Chemotherapy, 1983
- Comparative activities of norfloxacin and fifteen other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa strainsAntimicrobial Agents and Chemotherapy, 1983